Inactive Instrument

AB-BIOTICS SA Stock BME

Biotechnology & Medical Research

AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Companyâ€™s pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	62.54M 53.82M 50.64M 46.26M 86.53M 5.91B 86.77M 598M 232M 3.03B 235M 230M 9.76B	P/E 2017	-21.2x	P/E 2018	31.7x
Enterprise Value	60.11M 51.72M 48.66M 44.45M 83.16M 5.67B 83.39M 575M 223M 2.91B 226M 221M 9.38B	EV / Sales 2017	2.22x	EV / Sales 2018	2.88x
Free-Float	31.56%	Yield 2017 *	-	Yield 2018	-

22-05-31	AB-Biotics, S.A. acquired Alifarm S.A. for EUR 3.5 million.	CI
19-11-06	Kaneka Europe Holding Company N.V. completed the acquisition of 18.21% stake in AB-Biotics, S.A.	CI
19-09-02	Kaneka Europe Holding Company N.V. made an offer to acquire remaining 33.67% stake in AB-Biotics, S.A. for €21.2 million.	CI
19-08-15	Kaneka Corporation has completed the voluntary offer to acquire an additional 26.57% stake in AB-Biotics, S.A. for €16.7 million.	CI
19-07-09	Kaneka Corporation made a voluntary public offer to acquire the remaining 60.24% stake in AB-Biotics, S.A. for €37.9 million.	CI
19-03-21	Ab-Biotics Sa Reports Earnings Results for the Full Year Ended December 31, 2018	CI
18-05-10	Kaneka Corporation Concludes License Agreement with AB-Biotics for Production and Sales of its Probiotics Products	CI
18-04-04	Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
18-04-02	Kaneka Americas Holding Inc. enters into Licensing Agreement with AB-Biotics, S.A	CI
18-03-27	Kaneka Corporation signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.	CI
18-03-15	Corporacion Ivamosa and Gestion Y Administracion Mobiliaria, S.A. acquired 10% stake in AB-Biotics, S.A..	CI
17-11-07	Frutarom Industries Ltd. acquired AB-Fortis from AB-Biotics, S.A..	CI
16-10-24	AB-Biotics SA announced a financing transaction	CI

Director	Title	Age	Since
Sergi Audivert Brugué CHM	Chairman	-	-
Miquel Àngel Bonachera Sierra BRD	Director/Board Member	-	2004-04-22
Kazuhiko Fujii BRD	Director/Board Member	65	2018-07-01

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB-BIOTICS SA	-.--%	-.--%	-	-	69.57M
IOVANCE BIOTHERAPEUTICS, INC.	+1.03%	+9.74%	+299.55%	+42.93%	3.94B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-1.18%	-3.61%	+86.48%	+256.53%	3.92B
VERACYTE, INC.	-4.79%	-1.87%	+34.93%	+59.29%	3.59B
CAREDX, INC.	+2.05%	+2.19%	+288.40%	+422.92%	2.58B
BGI GENOMICS CO., LTD.	-1.65%	-6.73%	-26.25%	-32.04%	2.14B
FREENOME, INC.	-3.49%	+10.28%	+54.60%	-	1.82B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.68%	-4.69%	+210.17%	-28.93%	1.1B
SEEGENE, INC.	+1.11%	-10.52%	+24.12%	+41.15%	1.06B
CURIOX BIOSYSTEMS CO., LTD	-1.55%	-11.92%	+9.29%	+49.84%	613M
Average	-0.91%	-0.99%	+109.03%	+101.46%	2.31B
Weighted average by Cap.	-1.10%	+0.19%	+129.76%	+129.47%

	2017	2018
Net sales	7.72M 6.64M 6.25M 5.71M 10.68M 729M 10.71M 73.85M 28.66M 374M 28.99M 28.36M 1.2B	12.59M 10.84M 10.2M 9.31M 17.42M 1.19B 17.47M 120M 46.75M 610M 47.29M 46.26M 1.97B
Net income	-895K -770K -724K -662K -1.24M -84.48M -1.24M -8.56M -3.32M -43.34M -3.36M -3.29M -140M	1.22M 1.05M 986K 901K 1.69M 115M 1.69M 11.65M 4.52M 59.01M 4.57M 4.47M 190M
Net Debt	-1.86M -1.6M -1.5M -1.37M -2.57M -175M -2.58M -17.77M -6.9M -90M -6.98M -6.82M -290M	-2.44M -2.1M -1.97M -1.8M -3.37M -230M -3.38M -23.33M -9.05M -118M -9.16M -8.96M -381M

AB-BIOTICS SA Stock BME

Stocks

Biotechnology & Medical Research

Valuation : AB-BIOTICS SA

Latest news : AB-BIOTICS SA

Managers and Directors : AB-BIOTICS SA

Bio Diagnostics & Testing

Financials

Company Profile